Vistagen therapeutics, inc.
VTGN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
VTGN 近期報酬表現
-1.86%
Vistagen therapeutics, inc.
2.06%
同產業平均
-0.34%
S&P500
與 VTGN 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TNGX | Tango therapeutics inc | 4 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
NKTR | Nektar therapeutics | 4 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
PSTX | Poseida therapeutics inc | 3 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
RENB | Renovaro inc | 1 分 | 1 分 | 1 分 | - | 1 分 | |
ETON | Eton pharmaceuticals inc | 2 分 | 2 分 | 3 分 | 2 分 | 1 分 |
- TNGX Tango therapeutics inc價值 4 分趨勢 2 分波段 2 分籌碼 3 分股利 1 分查看更多
VTGN 公司資訊
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.